Genitourinary cancer highlights of ESMO 2023 Congress

Silke Gillessen explains the most important stories in GU cancers at ESMO 2023. Studies such as: - EV-302/KEYNOTE-A39 trial: Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy - CheckMate 901 trial: the first Phase 3 trial with an immunotherapy-based combination to show statistically significant and clinically meaningful survival benefit over standard-of-care cisplatin-based chemotherapy in the first-line treatment of this patient population - PSMAfore: 177Lu-PSMA-617 improves rPFS in taxane-naïve metastatic castration-resistant prostate cancer - RENOTORCH: a randomized, open-label, phase 3 study of toripalimab combined with axitinib versus sunitinib for the first line treatment of advanced renal cell carcinoma - LITESPARK-005 study: comparing belzutifan to everolimus in patients with previously treated advanced clear cell renal cell carcinoma Video: https://medicaldigest.org/scientific-contents/interview:genitourinary-cancer-highlights-esmo-2023-congress